Protalix BioTherapeutics (PLX) Net Cash Flow (2010 - 2026)

Protalix BioTherapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at $26.4 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 9078.91% year-over-year to $26.4 million in Q1 2026; TTM through Mar 2026 was $21.7 million, a 71.29% increase from a year earlier, with the FY2025 full-year figure at -$5.0 million, down 29.08% from the prior year.
• Net Cash Flow rose to $26.4 million in Q1 2026 per PLX's latest filing, from $1.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $26.4 million in Q1 2026 and bottomed at -$27.8 million in Q3 2023.
• The 5-year median for Net Cash Flow is -$294000.0 (2025), against an average of $1.2 million.
• Across the five-year window, Net Cash Flow plunged 1483.83% in 2022 and soared 9078.91% in 2026, its largest moves.
• Year by year, Net Cash Flow stood at $6.4 million in 2022, then slumped by 49.31% to $3.3 million in 2023, then plunged by 336.8% to -$7.7 million in 2024, then surged by 113.81% to $1.1 million in 2025, then soared by 2381.02% to $26.4 million in 2026.
• Per Business Quant, the three latest PLX Net Cash Flow figures stand at $26.4 million (Q1 2026), $1.1 million (Q4 2025), and -$4.2 million (Q3 2025).